| Title: |
Economic Issues in Heart Failure in the United States |
| Authors: |
Heidenreich, Paul A; Fonarow, Gregg C; Opsha, Yekaterina; Sandhu, Alexander T; Sweitzer, Nancy K; Warraich, Haider J; Chair, HFSA Scientific Statement Committee Members; Butler, Javed; Hsich, Eileen; Pressler, Susan Bennett; Shah, Kevin; Taylor, Kenneth; Sabe, Marwa; Ng, Tien |
| Source: |
Journal of Cardiac Failure, vol 28, iss 3 |
| Publisher Information: |
eScholarship, University of California |
| Publication Year: |
2022 |
| Collection: |
University of California: eScholarship |
| Subject Terms: |
32 Biomedical and Clinical Sciences (for-2020); 3201 Cardiovascular Medicine and Haematology (for-2020); 3202 Clinical Sciences (for-2020); Burden of Illness (rcdc); Cost Effectiveness Research (rcdc); Health Services (rcdc); Cardiovascular (rcdc); Comparative Effectiveness Research (rcdc); Heart Disease (rcdc); Clinical Research (rcdc); 8.2 Health and welfare economics (hrcs-rac); 8.1 Organisation and delivery of services (hrcs-rac); Cardiovascular (hrcs-hc); 3 Good Health and Well Being (sdg); Adrenergic beta-Antagonists (mesh); Angiotensin Receptor Antagonists (mesh); Angiotensin-Converting Enzyme Inhibitors (mesh); Cost-Benefit Analysis (mesh); Heart Failure (mesh); Hospitalization (mesh); Humans (mesh); Mineralocorticoid Receptor Antagonists (mesh); United States (mesh); HFSA Scientific Statement Committee Members Chair; 1102 Cardiorespiratory Medicine and Haematology (for); 1103 Clinical Sciences (for); 1110 Nursing (for); Cardiovascular System & Hematology (science-metrix) |
| Subject Geographic: |
453 - 466 |
| Description: |
The cost of heart failure care is high owing to the cost of hospitalization and chronic treatments. Heart failure treatments vary in their benefit and cost. The cost effectiveness of therapies can be determined by comparing the cost of treatment required to obtain a certain benefit, often defined as an increase in 1 year of life. This review was sponsored by the Heart Failure Society of America and describes the growing economic burden of heart failurefor patientsand the health care system in the UnitedStates. It also provides a summary of the cost effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure. Many medications that are no longer under patent are inexpensive and highly cost-effective. These include angiotensin-converting enzyme inhibitors, beta-blockers and mineralocorticoid receptor antagonists. In contrast, more recently developed medications and devices, vary in cost effectiveness, and often have high out-of-pocket costs for patients. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
qt19s4d7rg; https://escholarship.org/uc/item/19s4d7rg; https://escholarship.org/content/qt19s4d7rg/qt19s4d7rg.pdf |
| DOI: |
10.1016/j.cardfail.2021.12.017 |
| Availability: |
https://escholarship.org/uc/item/19s4d7rg; https://escholarship.org/content/qt19s4d7rg/qt19s4d7rg.pdf; https://doi.org/10.1016/j.cardfail.2021.12.017 |
| Rights: |
public |
| Accession Number: |
edsbas.D4C2C866 |
| Database: |
BASE |